Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion
Identifieur interne : 006295 ( Main/Exploration ); précédent : 006294; suivant : 006296Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion
Auteurs : M. E. Rodriguez [Espagne] ; M. R. Luquin [Espagne] ; G. Lera [Espagne] ; G. Delgado [Espagne] ; J. M. Salazar [Espagne] ; Obeso [Espagne]Source :
- Movement Disorders [ 0885-3185 ] ; 1990.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Bipolar Disorder (complications), Bipolar Disorder (drug therapy), Case study, Chemotherapy, Dopamine agonist, Dopamine agonists, Ergolines (therapeutic use), Human, Humans, Lisuride (therapeutic use), Lisuride infusion, Male, Malignant syndrome, Nervous system diseases, Neuroleptic, Neuroleptic Malignant Syndrome (drug therapy), Neuroleptic drugs, Subcutaneous administration, Toxicity, Treatment.
- MESH :
- chemical , therapeutic use : Ergolines, Lisuride.
- complications : Bipolar Disorder.
- drug therapy : Bipolar Disorder, Neuroleptic Malignant Syndrome.
- Adult, Humans, Male.
Abstract
A schizophrenic patient developed a characteristic clinical picture of neuroleptic malignant syndrome (NMS) while admitted to the hospital during an exacerbation of his psychiatric symptoms. Oral treatment of the NMS with bromocriptine (7.5 mg/day) or levodopa/carbidopa (125/12.5 mg) provoked intense vomiting in spite of domperidone (60 mg/day), which led to their discontinuation. In view of the deterioration of the symptoms, treatment was begun with lisuride (1–2 mg/24 h) subcutaneously. An obvious improvement was shown in 24 h, but levodopa/carbidopa (125/12.5 mg t.d.s. orally) had to be added later to achieve complete resolution of the NMS. During the recovery phase, while being treated with subcutaneous lisuride infusion and levodopa (p.o.), the patient presented with confusion, agitation, and hallucination. Lisuride infusion was stopped and levodopa was continued until complete resolution of the NMS. This case indicates that parenteral administration of lisuride or other dopamine agents such as levodopa (i.v.) or apomorphine (s.c.) may be considered an effective and practical way of treating NMS, particularly when the patient's condition makes it difficult or impossible to use other dopaminergic drugs by the oral route.
Url:
DOI: 10.1002/mds.870050215
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003149
- to stream Istex, to step Curation: 003149
- to stream Istex, to step Checkpoint: 004384
- to stream PubMed, to step Corpus: 004E85
- to stream PubMed, to step Curation: 004E85
- to stream PubMed, to step Checkpoint: 004E94
- to stream Ncbi, to step Merge: 003948
- to stream Ncbi, to step Curation: 003948
- to stream Ncbi, to step Checkpoint: 003948
- to stream Main, to step Merge: 009629
- to stream PascalFrancis, to step Corpus: 003956
- to stream PascalFrancis, to step Curation: 002E69
- to stream PascalFrancis, to step Checkpoint: 003936
- to stream Main, to step Merge: 009712
- to stream Main, to step Curation: 006295
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion</title><author><name sortKey="Rodriguez, M E" sort="Rodriguez, M E" uniqKey="Rodriguez M" first="M. E." last="Rodriguez">M. E. Rodriguez</name></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name></author><author><name sortKey="Lera, G" sort="Lera, G" uniqKey="Lera G" first="G." last="Lera">G. Lera</name></author><author><name sortKey="Delgado, G" sort="Delgado, G" uniqKey="Delgado G" first="G." last="Delgado">G. Delgado</name></author><author><name sortKey="Salazar, J M" sort="Salazar, J M" uniqKey="Salazar J" first="J. M." last="Salazar">J. M. Salazar</name></author><author><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C54C24A01D841F388DFF1FF3BA4A91CEF356A983</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1002/mds.870050215</idno><idno type="url">https://api.istex.fr/document/C54C24A01D841F388DFF1FF3BA4A91CEF356A983/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003149</idno><idno type="wicri:Area/Istex/Curation">003149</idno><idno type="wicri:Area/Istex/Checkpoint">004384</idno><idno type="wicri:doubleKey">0885-3185:1990:Rodriguez M:neuroleptic:malignant:syndrome</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2325680</idno><idno type="wicri:Area/PubMed/Corpus">004E85</idno><idno type="wicri:Area/PubMed/Curation">004E85</idno><idno type="wicri:Area/PubMed/Checkpoint">004E94</idno><idno type="wicri:Area/Ncbi/Merge">003948</idno><idno type="wicri:Area/Ncbi/Curation">003948</idno><idno type="wicri:Area/Ncbi/Checkpoint">003948</idno><idno type="wicri:doubleKey">0885-3185:1990:Rodriguez M:neuroleptic:malignant:syndrome</idno><idno type="wicri:Area/Main/Merge">009629</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:91-0150664</idno><idno type="wicri:Area/PascalFrancis/Corpus">003956</idno><idno type="wicri:Area/PascalFrancis/Curation">002E69</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003936</idno><idno type="wicri:doubleKey">0885-3185:1990:Rodriguez M:neuroleptic:malignant:syndrome</idno><idno type="wicri:Area/Main/Merge">009712</idno><idno type="wicri:Area/Main/Curation">006295</idno><idno type="wicri:Area/Main/Exploration">006295</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion</title><author><name sortKey="Rodriguez, M E" sort="Rodriguez, M E" uniqKey="Rodriguez M" first="M. E." last="Rodriguez">M. E. Rodriguez</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Lera, G" sort="Lera, G" uniqKey="Lera G" first="G." last="Lera">G. Lera</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Delgado, G" sort="Delgado, G" uniqKey="Delgado G" first="G." last="Delgado">G. Delgado</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Service of Neurology and Psychiatry, Hospital Provincial de Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Salazar, J M" sort="Salazar, J M" uniqKey="Salazar J" first="J. M." last="Salazar">J. M. Salazar</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Service of Neurology and Psychiatry, Hospital Provincial de Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Movement Disorders Unit, Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1990">1990</date><biblScope unit="vol">5</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="170">170</biblScope><biblScope unit="page" to="172">172</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C54C24A01D841F388DFF1FF3BA4A91CEF356A983</idno><idno type="DOI">10.1002/mds.870050215</idno><idno type="ArticleID">MDS870050215</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Bipolar Disorder (complications)</term><term>Bipolar Disorder (drug therapy)</term><term>Case study</term><term>Chemotherapy</term><term>Dopamine agonist</term><term>Dopamine agonists</term><term>Ergolines (therapeutic use)</term><term>Human</term><term>Humans</term><term>Lisuride (therapeutic use)</term><term>Lisuride infusion</term><term>Male</term><term>Malignant syndrome</term><term>Nervous system diseases</term><term>Neuroleptic</term><term>Neuroleptic Malignant Syndrome (drug therapy)</term><term>Neuroleptic drugs</term><term>Subcutaneous administration</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ergolines</term><term>Lisuride</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Bipolar Disorder</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bipolar Disorder</term><term>Neuroleptic Malignant Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Humans</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term><term>Etude cas</term><term>Homme</term><term>Lisuride</term><term>Neuroleptique</term><term>Stimulant dopaminergique</term><term>Syndrome malin</term><term>Système nerveux pathologie</term><term>Toxicité</term><term>Traitement</term><term>Voie souscutanée</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A schizophrenic patient developed a characteristic clinical picture of neuroleptic malignant syndrome (NMS) while admitted to the hospital during an exacerbation of his psychiatric symptoms. Oral treatment of the NMS with bromocriptine (7.5 mg/day) or levodopa/carbidopa (125/12.5 mg) provoked intense vomiting in spite of domperidone (60 mg/day), which led to their discontinuation. In view of the deterioration of the symptoms, treatment was begun with lisuride (1–2 mg/24 h) subcutaneously. An obvious improvement was shown in 24 h, but levodopa/carbidopa (125/12.5 mg t.d.s. orally) had to be added later to achieve complete resolution of the NMS. During the recovery phase, while being treated with subcutaneous lisuride infusion and levodopa (p.o.), the patient presented with confusion, agitation, and hallucination. Lisuride infusion was stopped and levodopa was continued until complete resolution of the NMS. This case indicates that parenteral administration of lisuride or other dopamine agents such as levodopa (i.v.) or apomorphine (s.c.) may be considered an effective and practical way of treating NMS, particularly when the patient's condition makes it difficult or impossible to use other dopaminergic drugs by the oral route.</div></front></TEI><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Rodriguez, M E" sort="Rodriguez, M E" uniqKey="Rodriguez M" first="M. E." last="Rodriguez">M. E. Rodriguez</name></noRegion><name sortKey="Delgado, G" sort="Delgado, G" uniqKey="Delgado G" first="G." last="Delgado">G. Delgado</name><name sortKey="Lera, G" sort="Lera, G" uniqKey="Lera G" first="G." last="Lera">G. Lera</name><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M. R." last="Luquin">M. R. Luquin</name><name sortKey="Obeso" sort="Obeso" uniqKey="Obeso" last="Obeso">Obeso</name><name sortKey="Salazar, J M" sort="Salazar, J M" uniqKey="Salazar J" first="J. M." last="Salazar">J. M. Salazar</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006295 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006295 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C54C24A01D841F388DFF1FF3BA4A91CEF356A983
|texte= Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion
}}
| This area was generated with Dilib version V0.6.23. |  |